Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

Longchuan ZHU; Wei WU; Dakai GAN; Wei ZHANG; Yizhen XU; Molong XIONG

doi:10.12449/JCH240214

Volume 40 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(2): 306-311

PDF( 922 KB)

Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.12449/JCH240214

1.
Department of Hepatology，The Ninth Hospital of Nanchang，Nanchang 330002，China
2.
Department of Gastroenterology，Jiangxi Provincial Children’s Hospital，Nanchang 330006，China

Research funding:

Key Research and Development Program of Jiangxi Province (20181BBG78010)

More Information

Corresponding author: ZHU Longchuan， zlcy1984@sina.com （ORCID： 0000-0002-4461-6195）
Received Date: 2023-08-28
Accepted Date: 2023-10-16
Published Date: 2024-02-19

Abstract

Abstract

Objective To investigate the clinical application value of a predictive model for the efficacy of third-generation cephalosporin in the treatment of community-acquired spontaneous bacterial peritonitis （CASBP）. Methods This prospective study was conducted among 50 patients with liver cirrhosis and CASBP who were admitted to The Ninth Hospital of Nanchang from January 2021 to June 2022， and the patients were randomly divided into optimized treatment group and traditional treatment group， with 25 patients in each group. The patients in the optimized treatment group received ceftazidime or imipenem for initial treatment based on the above predictive model， and those in the traditional treatment group received ceftazidime for initial treatment， with the subsequent use of antibiotics adjusted based on the efficacy of initial treatment. The two groups were compared in terms of the response rate of initial treatment， cure rate on day 5， and 30-day mortality rate. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. Results All patients completed the study. The optimized treatment group had a significantly higher response rate of initial treatment than the traditional treatment group （88.0% vs 60.0%， χ²=5.094， P=0.024）， while there was no significant difference in the cure rate on day 5 between the two groups （80.0% vs 56.6%， χ²=3.309， P=0.069）. As for the patients who received ceftazidime for initial treatment， the optimized treatment group had a significantly higher response rate of initial treatment than the traditional treatment group （88.9% vs 60.0%， χ²=4.341， P=0.037）， while there was no significant difference in the cure rate on day 5 between the two groups （83.3% vs 56.0%， χ²=2.425， P=0.119）. There was no significant difference in 30-day mortality rate between the two groups （8.0% vs 20.0%， χ²=0.664， P=0.415）. For all patients， there was a significant association between response of initial treatment and cure on day 5 （odds ratio ［OR］=9.643， 95% confidence interval ［CI］： 2.292‍ — ‍40.564） and between cure on day 5 and 30-day mortality （OR=0.138， 95%CI： 0.023‍ — ‍0.813）. Conclusion This predictive model for efficacy helps clinicians to identify the patients who can benefit from third-generation cephalosporin treatment and improve the efficacy of third-generation cephalosporin in the initial empirical treatment of CASBP.
- Liver Cirrhosis,
- Peritonitis,
- Community-Acquired Infections,
- Cephalosporins,
- Treatment Outcome

FullText(HTML)

References(18)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[2]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 74( 2): 1014- 1048. DOI: 10.1002/hep.31884.
[3]	ZHU LC, WU W, ZOU B, et al. Efficacy predictors of third-generation cephalosporins in treating spontaneous bacterial peritonitis[J]. Medicine(Baltimore), 2022, 101( 40): e30164. DOI: 10.1097/MD.0000000000030164.
[4]	ZHU LC, WU W, ZOU B, et al. Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis[J]. J Clin Hepatol, 2022, 38( 11): 2499- 2504. DOI: 10.3969/j.issn.1001-5256.2022.11.012. 朱龙川, 吴蔚, 邹波, 等. 第三代头孢菌素治疗社区获得性自发性细菌性腹膜炎的疗效预测模型[J]. 临床肝胆病杂志, 2022, 38( 11): 2499- 2504. DOI: 10.3969/j.issn.1001-5256.2022.11.012.
[5]	AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70( 1): 9- 29. DOI: 10.1136/gutjnl-2020-321790.
[6]	JINDAL A, KUMAR M, BHADORIA AS, et al. A randomized open label study of‘imipenem vs. cefepime’ in spontaneous bacterial peritonitis[J]. Liver Int, 2016, 36( 5): 677- 687. DOI: 10.1111/liv.12985.
[7]	PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60( 8): 646- 649. DOI: 10.1002/bjs.1800600817.
[8]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33( 2): 464- 470. DOI: 10.1053/jhep.2001.22172.
[9]	JIN PH. Medical statistical methods[M]. 2^nd ed. Shanghai: Fudan University Press, 2003: 469- 471. 金丕焕. 医用统计方法[M]. 第2版. 上海: 复旦大学出版社, 2003: 469- 471.
[10]	FIORE M, GENTILE I, MARAOLO AE, et al. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30( 3): 329- 336. DOI: 10.1097/MEG.0000000000001057.
[11]	LIN QT, ZHU HD. Establishment of the model for predicting the initial therapeutic effect of hospital-acquired methicillin-resistant staphylococcus aureus pneumonia[J]. Chin J Crit Care Med, 2022, 42( 5): 393- 400. DOI: 10.3969/j.issn.1002-1949.2022.05.004. 林清婷, 朱华栋. 建立医院获得性耐甲氧西林金黄色葡萄球菌肺炎的初始治疗效果预测模型的研究[J]. 中国急救医学, 2022, 42( 5): 393- 400. DOI: 10.3969/j.issn.1002-1949.2022.05.004.
[12]	LI C, SU HB, LIU XY, et al. Clinical outcome of patients with acute-on-chronic liver failure and bacterial infection after 72 hours of anti-infective therapy[J]. J Clin Hepatol, 2019, 35( 1): 147- 152. DOI: 10.3969/j.issn.1001-5256.2019.01.028. 李晨, 苏海滨, 刘晓燕, 等. 慢加急性肝衰竭合并细菌感染患者抗感染治疗72小时的效果及影响因素[J]. 临床肝胆病杂志, 2019, 35( 1): 147- 152. DOI: 10.3969/j.issn.1001-5256.2019.01.028.
[13]	LEE CH, KANG HJ, YU SY, et al. Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma[J]. Sci Rep, 2023, 13( 1): 6067. DOI: 10.1038/s41598-023-32006-8.
[14]	PIANO S, FASOLATO S, SALINAS F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial[J]. Hepatology, 2016, 63( 4): 1299- 1309. DOI: 10.1002/hep.27941.
[15]	YIM HJ, KIM TH, SUH SJ, et al. Response-guided therapy with cefotaxime, ceftriaxone, or ciprofloxacin for spontaneous bacterial peritonitis: A randomized trial: A validation study of 2021 AASLD practice guidance for SBP[J]. Am J Gastroenterol, 2023, 118( 4): 654- 663. DOI: 10.14309/ajg.0000000000002126.
[16]	SAFFO S, TO UK, SANTOIEMMA PP, et al. Changes in ascitic fluid polymorphonuclear cell count after antibiotics are associated with mortality in spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2022, 20( 5): e1201- e1204. DOI: 10.1016/j.cgh.2021.07.019.
[17]	SARWAR S, TARIQUE S, WARIS U, et al. Cephalosporin resistance in community acquired spontaneous bacterial peritonitis[J]. Pak J Med Sci, 2019, 35( 1): 4- 9. DOI: 10.12669/pjms.35.1.17.
[18]	SANGLODKAR U, JAIN M, VENKATARAMAN J. Predictors of immediate and short-term mortality in spontaneous bacterial peritonitis[J]. Indian J Gastroenterol, 2020, 39( 4): 331- 337. DOI: 10.1007/s12664-020-01040-z.

Relative Articles

[1]	Xiumin CHEN, Shenglong LIN, Xiangmei WANG, Huaxi MA, Dongqing ZHANG, Ziyuan LIAO, Minghua LIN, Haibing GAO. Association of energy metabolic markers with the short-term risk of spontaneous bacterial peritonitis in patients with decompensated hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1311-1316. doi: 10.3969/j.issn.1001-5256.2022.06.018
[2]	Longchuan ZHU, Wei WU, Bo ZOU, Dakai GAN, Xue LIN, Wei ZHOU, Molong XIONG. Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2499-2504. doi: 10.3969/j.issn.1001-5256.2022.11.012
[3]	Ping JIANG, Rencheng DOU, Zijin CUI, Yinni TONG, Chen LI, Shanshan JIANG, Yun BAI, Jimin ZHENG, Cunkai WANG, Yuzhen WANG. Value of albumin-bilirubin score combined with neutrophil count and procalcitonin in ascites in predicting spontaneous bacterial peritonitis in patients with cirrhotic ascites[J]. Journal of Clinical Hepatology, 2021, 37(9): 2097-2101. doi: 10.3969/j.issn.1001-5256.2021.09.019
[4]	Shuping CHENG, Ming LI, Qingyu ZHANG, Shiyun TAN. Efficacy and safety of rifaximin in the prevention of spontaneous bacterial peritonitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(2): 318-325. doi: 10.3969/j.issn.1001-5256.2021.02.015
[5]	Yu LIU, Yuyi ZHANG, Ying ZOU, Wei YUAN, Hongying GUO, Xue MEI, Jiefei WANG, Zhiping QIAN. Association between intestinal microecology and spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2021, 37(2): 425-428. doi: 10.3969/j.issn.1001-5256.2021.02.037
[6]	Zhenjiao GAO, Xingshun QI, Hongyu LI, Xiaozhong GUO. A case of spontaneous bacterial peritonitis caused by Neisseria. subflava in liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 153-155. doi: 10.3969/j.issn.1001-5256.2021.01.030
[7]	Xue ShuWen, Zhao QianShu, Li XiaoKe, Yang QianQian, Zhou Qi, Guo XiaoLin, Ji HuiFan. A case of recurrent fever and lumbago in hepatic cirrhosis complicated by spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2289-2291. doi: 10.3969/j.issn.1001-5256.2019.10.032
[8]	Zhang YaNan, Jiang Chang, Xu Ying, Gao YanHang. Early diagnosis of spontaneous bacterial peritonitis in liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1851-1853. doi: 10.3969/j.issn.1001-5256.2019.08.045
[9]	Li BeiLing, Zhong GuoTao, Chen JinJun. Current status of the diagnose and treatment of spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2019, 35(9): 2079-2081. doi: 10.3969/j.issn.1001-5256.2019.09.043
[10]	Zhu LongChuan, Gan DaKai, Hu QingQing, Xiong MoLong. Predictive factors for third-generation cephalosporin-resistant spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1501-1504. doi: 10.3969/j.issn.1001-5256.2019.07.016
[11]	Liu ZhengFang, Huang Wei, Li Qin. A risk factors analysis of acute-on-chronic liver failure complicated by spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2017, 33(4): 719-722. doi: 10.3969/j.issn.1001-5256.2017.04.024
[12]	Yang YaLin, Xu ZhiJie. Postoperative infection in laparoscopic cholecystectomy in treatment of acute cholecystitis complicated by choleperitonitis[J]. Journal of Clinical Hepatology, 2017, 33(1): 98-101. doi: 10.3969/j.issn.1001-5256.2017.01.021
[13]	Li XiaoLou, Chen MingSheng, Gan QiaoRong, Jiang XiaoYan, Chen Li. Risk factors for antibiotic prophylaxis failure in patients with liver cirrhosis and upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2016, 32(2): 288-291. doi: 10.3969/j.issn.1001-5256.2016.02.018
[14]	Song YuanYuan, Jiang YuYong. Research advances in diagnosis and treatment of spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1188-1191. doi: 10.3969/j.issn.1001-5256.2016.06.040
[15]	Zhang JuLing, Geng Wei, Cui EnBo, Yuan Yuan, Zhang ChengLong, Chen SuMing, Jia TianYe, Wang Huan, Bao ChunMei, Qu Fen. Analysis of pathogenic features of liver cirrhosis with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2015, 31(3): 407-412. doi: 10.3969/j.issn.1001-5256.2015.03.023
[16]	Yang ZhengMao, Shi WenJuan, Zhou Jian, Wang ZhaoXun. Curative effect of peritoneal lavage in treatment of cirrhotic patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2015, 31(3): 384-386. doi: 10.3969/j.issn.1001-5256.2015.03.017
[17]	Wu HaiQing, Wang Hui. Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascites[J]. Journal of Clinical Hepatology, 2012, 28(9): 651-653.
[18]	Li RuGui, Tan HuaBing, Zhan GuoQing, Zhang WeiWei, Hu Bo. A retrospective analysis of the factors influencing the prognosis of liver cirrhosis combined with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2011, 27(2): 170-173.
[19]	Mou XiaoHui. Management of spontaneous bacterial peritonitis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1015-1018.
[20]	Liang Jing, Kan ZhiChao, Zhang JianDong. The clinical characteristics and treatment of liver failure patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 621-623.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (376) PDF downloads(46)

Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.12449/JCH240214

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.12449/JCH240214

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content